Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

18-Fluorodeoxyglucose imaging in oncology.

J A Harolds1

  • 1Integris Baptist Medical Center, Oklahoma City 73112-4481, USA.

The Journal of the Oklahoma State Medical Association
|October 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Residents: be aggressive in your own education!

Academic radiology·1998
Same author

Tips for getting a position with an independent private practice radiology group.

Academic radiology·1998
Same author

Correlation of gallbladder ejection fraction with pathologic grade for chronic inflammation.

Southern medical journal·1998
Same author

Technetium-99m-albumin colloid lymphoscintigraphy in postoperative lymphocele.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1996
Same author

Residency evaluations.

Academic radiology·1996
Same author

The radiology resident in difficulty.

Academic radiology·1995

18-Fluorodeoxyglucose (FDG) scans are valuable diagnostic tools for cancer staging. Positron Emission Tomography (PET) or PET/SPECT imaging is essential for these oncologic studies, aiding healthcare providers in patient evaluation.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Medical Imaging

Background:

  • 18-Fluorodeoxyglucose (FDG) is a radiopharmaceutical used in diagnostic imaging.
  • Positron Emission Tomography (PET) and hybrid PET/SPECT scanners are required for oncologic studies utilizing FDG.
  • Dissemination of knowledge regarding FDG scan utility and limitations is crucial for healthcare providers.

Purpose of the Study:

  • To describe the application of 18-Fluorodeoxyglucose (FDG) scans in the diagnostic evaluation of cancer patients.
  • To inform healthcare providers about the evolving uses and limitations of FDG scans in oncology.

Main Methods:

  • Utilizing 18-Fluorodeoxyglucose (FDG) as a radiotracer.
  • Employing dedicated Positron Emission Tomography (PET) or hybrid PET/SPECT imaging units for oncologic studies.

Related Experiment Videos

Main Results:

  • FDG scans are currently used for staging specific cancers, including non-small cell lung carcinoma, malignant melanoma, Hodgkin's disease, non-Hodgkin's lymphoma, colorectal carcinoma, and head and neck carcinoma.
  • The availability of PET and PET/SPECT scanners facilitates these diagnostic evaluations.

Conclusions:

  • FDG scans represent an important diagnostic modality in oncology.
  • Effective utilization of FDG scans requires understanding their benefits and limitations in various cancer types.